Previous Article | Next Article ![]()
J Virol, May 1998, p. 4352-4363, Vol. 72, No. 5
CRC Institute for Cancer Studies,
Received 17 November 1997/Accepted 4 February 1998
In apparent contrast to earlier work on Epstein-Barr virus (EBV)
carriage in the general Caucasian population, in vitro virus isolations
from human immunodeficiency virus (HIV)-positive male homosexual
cohorts have shown frequent examples of multiple EBV infection and an
overall prevalence of type 2 EBV strains exceeding 30%. Here we ask to
what extent these findings might hold true in another
T-cell-immunocompromised cohort, HIV-positive hemophilic patients.
Resident EBV strains were rescued within lymphoblastoid cell lines
derived from the blood and throat washings of 39 such individuals,
using the same in vitro protocols of virus isolation as for the
homosexual cohort. A mean of 19 independent cell lines was made per
patient, and in each case the resident virus was characterized by
PCR-based viral genomic analysis and by immunoblotting to reveal the
viral "EBNAprint." By these criteria a significant proportion (14 of 39) of the hemophilic cohort carried more than one EBV strain,
suggesting that T-cell impairment does indeed sensitize virus carriers
to reinfection with new strains of exogenously transmitted virus.
However, the overall incidence of type 2 EBV infection was 10%, which
is close to that observed in the earlier work with healthy carriers and
substantially lower than that seen in HIV-positive homosexuals. We
infer that type 2 EBV is relatively rare in the general Caucasian
population but has become endemic in the homosexual community.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Epidemiology of Infection with Epstein-Barr Virus Types 1 and 2:
Lessons from the Study of a T-Cell-Immunocompromised Hemophilic
Cohort
*
Corresponding author. Mailing address: CRC Institute
for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TA, United Kingdom. Phone: 121-414-4492. Fax: 121-414-4486. E-mail: Williamsd{at}cancer.bham.ac.uk.
J Virol, May 1998, p. 4352-4363, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|